Short telomeres are associated with decreased cancer survival

At the end of 2010, JAMA published a large meta-analysis on telomere length and cancer incidence. JAMA is not usually my favorite journal for this kind of work, but the analysis was solid and the findings have held up. Worth a clean summary because the implication for an aging adult population is significant.

What the meta-analysis found

The analysis pooled data across multiple cohorts and divided participants into quartiles by telomere length. The shortest-quartile group had roughly a five-fold higher cancer incidence compared to the longest-quartile group. The two middle quartiles fell in between, with cancer risk decreasing roughly stepwise across the quartiles.

Beyond incidence, the analysis also found that the cancers occurring in the shortest-telomere group tended to be more aggressive and were diagnosed at later stages. The two findings together establish telomere length as a relevant risk marker, not just a curiosity.

The Danish survival study

A subsequent Danish cohort study looked at the question from a different angle. Among adults who had been diagnosed with cancer, those in the shortest-telomere quartile had the lowest post-diagnosis survival. The longest-telomere group had the highest. The relationship was approximately linear across the quartiles.

That second finding is the one that matters most for an audience already concerned with healthspan. It says that telomere maintenance is not just about whether you get cancer, but about how well you do if you have already had one or are at high risk.

Why the telomere story keeps coming up

The status quo in clinical medicine is hard to move. Most primary care doctors do not have telomere length on the routine screening list. Most insurance does not pay for the test. Most patients have never heard of it from their cardiologist or their oncologist. The literature, though, keeps growing. The question is when the clinical workflow will catch up to the data.

I have been talking about telomeres for over a decade. The volume of people who hear about telomeres for the first time through some other source, then circle back to me, has grown every year. That is the natural arc for a clinical concept moving from research to practice. It is roughly where omega-3 status sat fifteen years ago.

What to do about your telomeres, in order of cost

1. Read up on the field. Our book The Immortality Edge remains a reasonable lay-language starting point. Maria Blasco’s published work is available in PubMed for those who want to go deeper.
2. Run a clinically dosed fish oil. A reasonable starting place is around 3 to 4 grams of combined EPA and DHA per day, with food, then test your omega-3 index and adjust. Aim above 8 percent.
3. Add the supporting nutrients that the cohort data associates with slower telomere attrition. Vitamin D to 50 to 75 ng/mL. A real multivitamin with active B vitamins. CoQ10 in ubiquinol form for adults over 50. Carnosine if budget allows. These are the components of the Telomere Edge Packs for readers who want them packaged.
4. For those for whom budget allows. TA-65 remains the most-studied compound for actual telomerase activation in humans. It is the most expensive item on the list and the most proven.

What to expect over the next decade

More cohort data linking telomere length to disease incidence and survival. The signal will continue to strengthen. Occasional contrarian papers questioning specific findings will get disproportionate press because controversy sells. More telomerase activator products will hit the market, most without the supporting human data. And, eventually, telomere testing will move into the standard preventive workflow, the way lipid panels and HbA1c did before it.

Fish oil took roughly thirty years to move from fringe to mainstream cardiology. Telomere science is on a similar trajectory and may move faster given the broader interest in healthspan as a clinical concept.

— Doc